Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study.
antibiotic: antiviral
clinical research/practice
complication: infectious
infection and infectious agents - viral: BK/JC/polyoma
infectious disease
kidney transplantation/nephrology
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
18
01
2020
revised:
20
07
2020
accepted:
20
07
2020
pubmed:
3
8
2020
medline:
22
6
2021
entrez:
3
8
2020
Statut:
ppublish
Résumé
BK virus (BKV) replication occurs frequently in kidney transplant recipients (KTR), potentially leading to BKV-associated nephropathy (BKVAN) and graft loss. Patients with high titers of BKV-neutralizing antibodies (NAbs) are protected against BKV replication, and intravenous immunoglobulin (IVIg) infusion can increase NAb titers. We investigated whether early IVIg administration prevents BKV replication in patients with low NAb titers (<4 log
Identifiants
pubmed: 32741096
doi: 10.1111/ajt.16233
pii: S1600-6135(22)08343-5
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
329-337Informations de copyright
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons.
Références
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488-496.
Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant. 2005;5(3):582-594.
Borni-Duval C, Caillard S, Olagne J, et al. Risk factors for BK virus infection in the era of therapeutic drug monitoring. Transplantation. 2013;95(12):1498-1505.
Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014;312(20):2106-2114.
Krisl JC, Taber DJ, Pilch N, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol. 2012;7(6):1003-1009.
Pallet N, Burgard M, Quamouss O, et al. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation. 2010;89(12):1542-1544.
Petrov R, Elbahloul O, Gallichio MH, Stellrecht K, Conti DJ. Monthly screening for polyoma virus eliminates BK nephropathy and preserves renal function. Surg Infect. 2009;10(1):85-90.
Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant. 2019;34(7):1240-1250.
Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89(9):1057-1070.
Parajuli S, Astor BC, Kaufman D, et al. Which is more nephrotoxic for kidney transplants: BK nephropathy or rejection? Clin Transplant. 2018;32(4):e13216.
Hardinger K, Koch M, Bohl D, Storch G, Brennan D. BK-virus and the impact of preemptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10(2):407-415.
Cheungpasitporn W, Kremers WK, Lorenz E, et al. De novo donor-specific antibody following BK nephropathy: the incidence and association with antibody-mediated rejection. Clin Transplant. 2018;32(3):e13194.
Devresse A, Tinel C, Vermorel A, et al. No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience. Transpl Int. 2019;32(5):481-492.
Vu D, Shah T, Ansari J, Naraghi R, Min D. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc. 2015;47(2):394-398.
Anyaegbu EI, Almond PS, Milligan T, Allen WR, Gharaybeh S, Al-Akash SI. Intravenous immunoglobulin therapy in the treatment of BK viremia and nephropathy in pediatric renal transplant recipients. Pediatr Transplant. 2012;16(1):E19-E24.
Kable K, Davies CD, O'connell PJ, Chapman JR, Nankivell BJ. Clearance of BK virus nephropathy by combination antiviral therapy with intravenous immunoglobulin. Transplant Direct. 2017;3(4):e142.
Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81(1):117-120.
Sharma AP, Moussa M, Casier S, Rehman F, Filler G, Grimmer J. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant. 2009;13(1):123-129.
Hwang SD, Lee JH, Lee SW, Kim JK, Kim M-J, Song JH. High-dose intravenous immunoglobulin treatment of polyomavirus nephropathy developing after T cell-mediated rejection treatment: a case report. Transplant Proc. 2018;50(8):2575-2578.
Solis M, Velay A, Porcher R, et al. Neutralizing antibody-mediated response and risk of BK virus-associated nephropathy. J Am Soc Nephrol. 2018;29(1):326-334.
Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant. 2015;15(4):1014-1020.
Velay A, Solis M, Benotmane I, et al. Intravenous immunoglobulin administration significantly increases BKPyV genotype-specific neutralizing antibody titers in kidney transplant recipients. Antimicrob Agents Chemother. 2019;63(8):e00393-19.
Solis M, Meddeb M, Sueur C, et al. Sequence variation in amplification target genes and standards influences interlaboratory comparison of BK virus DNA load measurement. J Clin Microbiol. 2015;53(12):3842-3852.
Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, et al. Pretransplantation donor-recipient pair seroreactivity against BK polyomavirus predicts viremia and nephropathy after kidney transplantation. Am J Transplant. 2017;17(1):161-172.
Radtke J, Dietze N, Fischer L, et al. Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy. Transpl Infect Dis. 2016;18(6):850-855.
Schachtner T, Stein M, Babel N, Reinke P. The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplan. 2015;15(8):2159-2169.
Renner FC, Dietrich H, Bulut N, et al. The risk of polyomavirus-associated graft nephropathy is increased by a combined suppression of CD8 and CD4 cell-dependent immune effects. Transplant Proc. 2013;45(4):1608-1610.
Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant. 2007;7(12):2727-2735.
Berger SP, Sommerer C, Witzke O, et al. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from TRANSFORM study. Am J Transplant. 2019;19(11):3018-3034.
Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010;89(12):1462-1465.